title: Sustained-release celecoxib from incubated acrylic intraocular lenses suppresses lens epithelial cell growth in an ex vivo model of posterior capsule opacity.
abstract: OBJECTIVE
  To determine whether celecoxib (CXB) can be released from incubated intraocular lenses (IOLs) sufficiently to inhibit lens epithelial cell (LEC) growth in an ex vivo model of posterior capsule opacification (PCO).
  
  
  METHODS
  LEC growth was evaluated for 14 days in canine lens capsules (LCs) that had been exposed to media containing 20 μM CXB for 1-5 days. After the incubation of hydrophilic and hydrophobic IOLs in CXB solution, the determination of the in vitro release of CXB from the IOLs was performed for up to 28 days. The incubated and nonincubated IOLs were evaluated in the ex vivo model of PCO, and the rate of LEC growth was evaluated over 28 days.
  
  
  RESULTS
  The treatment of LCs with 20 μM CXB for 4 and 5 days completely inhibited LEC growth. LEC repopulation did not occur after the removal of CXB. IOLs incubated in CXB for 24 h resulted in a sustained release of CXB in vitro at levels theoretically sufficient to inhibit PCO. LCs in the ex vivo model of PCO treated with acrylic IOLs incubated in CXB had significantly suppressed LEC ingrowth compared with untreated and IOL-only LCs.
  
  
  CONCLUSIONS
  A 4-day treatment of LCs with a concentration of 20 μM CXB may effectively prevent PCO. IOLs incubated in CXB for 24 h resulted in a sustained release of CXB in vitro at levels sufficient to inhibit LEC growth in the ex vivo model of PCO. Further studies are needed to determine whether CXB-incubated IOLs can effectively prevent the development of PCO in vivo.
authors.affiliation: Department of Clinical Sciences, North Carolina State University, Raleigh, NC 27607, USA.
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Davis
authors.forename: Na Young
authors.initials: NY
authors.lastname: Yi
authors.forename: Jacklyn H
authors.initials: JH
authors.lastname: Salmon
authors.forename: Anna N
authors.initials: AN
authors.lastname: Charlton
authors.forename: Carmen M H
authors.initials: CM
authors.lastname: Colitz
authors.forename: Brian C
authors.initials: BC
authors.lastname: Gilger
mesh_terms: D000818:Animals; D002387:Cataract Extraction; D000068579:Celecoxib; D003318:Corneal Opacity / Q000473:pathology / Q000517:prevention & control*; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004285:Dogs; D004847:Epithelial Cells / Q000187:drug effects*; D004848:Epithelium / Q000187:drug effects / Q000254:growth & development; D066298:In Vitro Techniques; D007908:Lens, Crystalline / Q000166:cytology / Q000187:drug effects / Q000254:growth & development; D007910:Lenses, Intraocular; D019904:Polymethyl Methacrylate; D057852:Posterior Capsule of the Lens / Q000166:cytology / Q000187:drug effects / Q000473:pathology*; D011183:Postoperative Complications / Q000473:pathology / Q000517:prevention & control; D011720:Pyrazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013449:Sulfonamides / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D003692:Delayed-Action Preparations; D011720:Pyrazoles; D013449:Sulfonamides; D019904:Polymethyl Methacrylate; D000068579:Celecoxib